Active Ingredient(s): Efalizumab
FDA Approved: * October 27, 2003
Pharm Company: * GENENTECH
Category: Immunosuppressive

Efalizumab (trade name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis. As implied by the suffix -mab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection. Efalizumab binds to the CD11a[1] subunit of lymphocyte function-associated antigen 1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.